For the whole of September we are going to be dedicating this blog to exploring the data that we’re able to extract from CiteAb.
This means we plan to release a new market report based on CiteAb citation data every week for the rest of the month. Keep an eye out for monoclonal trends and an update to our company market report among other subjects!
The CiteAb antibody market datasets are based on analysis of hundreds of thousands of antibody citations and provide a quantitative view of the research antibody market and how it’s changing over time.
They are not based on user surveys or web usage statistics, providing a unique and independent view of the antibody market, allowing companies to make more informed product development and marketing decisions.
We produce these datasets to ensure the financial viability of CiteAb. We charge companies for providing them, creating income that allows us to keep CiteAb free to list and ranked only by citations. This means no company is able to pay to be top ranked, and ensures we remain impartial and provide the best possible service to our users.
Dr Andrew Chalmers, Founder of CiteAb, said: “We know that many of our readers are interested in the datasets produced by CiteAb, and therefore we always make a small sample of the data from each market report available for free. If you’d like to see this sample data for any of our past market reports (all of which are available on our blog) you can still contact us to obtain these.”
You can find out more about our market reports and datasets here. If you are interested in further details about any of our datasets simply drop email@example.com an email, and later this month we’ll offer a webinar so do join us if you have any questions you’d like to ask our team.
– David and the CiteAb team